Viridian Therapeutics
VRDN
29.96
-1.48
-4.71%
Viridian Therapeutics
US · VRDN
#2731 by market cap
Listed 1970
29.96
-1.48
-4.71%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About Viridian Therapeutics
Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
- Founded
- 2006
- CEO
- Mr. Stephen Mahoney
- Employees
- 252
- Headquarters
- Waltham, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- viridiantherapeutics.com
Company profile
- Exchange
- US
- Symbol
- VRDN
- Market-cap rank
- #2731
- Listing date
- 1970-01-01
- Market cap
- 3.40B
- Float cap
- 2.97B
- Shares out
- 113.56M
- Float shares
- 99.06M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Viridian Therapeutics discussion 0 comments